Core Viewpoint - Outlook Therapeutics has submitted a Type A meeting request to the FDA following a Complete Response Letter regarding its Biologics License Application for ONS-5010/LYTENAVA™ for wet AMD treatment, citing a deficiency in evidence of effectiveness [1][2] Group 1: Regulatory Developments - The Complete Response Letter identified a single deficiency related to the lack of substantial evidence of effectiveness and recommended additional confirmatory evidence [2] - Outlook Therapeutics believes the FDA's determination is inconsistent with the totality of evidence submitted, including data from a well-controlled study [2] - The company conducted informal meetings with the FDA prior to submitting the Type A meeting request to discuss the CRL [2] Group 2: Clinical Evidence - ONS-5010 is supported by data from the NORSE TWO Phase 3 trial, which showed statistically significant improvements in visual acuity at 12 months, meeting its primary endpoint [3] - NORSE EIGHT, another Phase 3 study, provided additional evidence of efficacy despite not meeting its primary endpoint at 8 weeks, showing consistent gains in visual acuity [4] - A comprehensive package of confirmatory evidence was submitted, including mechanistic and pharmacodynamic data demonstrating VEGF inhibition [5] Group 3: Safety and Manufacturing - ONS-5010 demonstrated a favorable safety profile, with ocular adverse reactions consistent with the control arm and no safety concerns raised by the FDA [6] - The product is supported by a fully domestic U.S. manufacturing supply chain, enhancing reliability and aligning with public health objectives [7] Group 4: Market Authorization - LYTENAVA™ has received Marketing Authorization in the EU and UK for wet AMD treatment and became commercially available in Germany and the UK in June 2025 [8] - It is the first authorized ophthalmic formulation of bevacizumab for treating wet AMD in the EU and UK [9] - Outlook Therapeutics is exploring collaborations for commercial and distribution partnerships in additional European countries and beyond [8]

Core Viewpoint - Outlook Therapeutics, Inc. has appointed Laura Cantrell as Vice President of Corporate Strategy and Business Development to enhance its strategic initiatives and shareholder value during a critical phase of the company's evolution [3][4]. Company Overview - Outlook Therapeutics is a biopharmaceutical company focused on developing and commercializing ONS-5010/LYTENAVA™ (bevacizumab-vikg) to improve the standard of care for retinal diseases [6]. - LYTENAVA™ is the first ophthalmic formulation of bevacizumab to receive marketing authorization from the European Commission and MHRA for treating wet AMD, with a commercial launch already commenced in Germany and the UK [6]. Leadership Appointment - Laura Cantrell brings over 20 years of experience in global corporate strategy, business development, and portfolio leadership within the biotechnology and pharmaceutical sectors [4][5]. - Cantrell has held senior roles at notable companies such as Medivation, BeiGene, Sobi, Axovant Sciences, and Genentech/Roche, and has been involved in significant licensing and acquisition initiatives, including Medivation's $14 billion acquisition by Pfizer [4][5]. Strategic Focus - In her new role, Cantrell will lead the business development strategy, focusing on strategic partnerships, licensing opportunities, and corporate development initiatives to support the company's growth [3][4]. - The company aims to advance its mission of delivering a differentiated ophthalmic formulation of bevacizumab while maximizing long-term shareholder value [3].

Core Viewpoint - Outlook Therapeutics, Inc. has granted stock options to new employees as part of their compensation package, indicating a strategic move to attract talent in the biopharmaceutical sector focused on retinal diseases [1][2]. Company Overview - Outlook Therapeutics is a biopharmaceutical company dedicated to the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg), aimed at enhancing the standard of care for retinal diseases [3]. - LYTENAVA™ is the first ophthalmic formulation of bevacizumab to receive marketing authorization from the European Commission and MHRA for treating wet age-related macular degeneration (wet AMD) [3]. - The company has commenced the commercial launch of LYTENAVA™ in Germany and the UK for the treatment of wet AMD [3]. Product Development - In the United States, ONS-5010/LYTENAVA™ is currently investigational, and if approved, it would be the first ophthalmic formulation of bevacizumab for retinal indications, including wet AMD [4].

Core Insights - Outlook Therapeutics, Inc. is participating in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025 [1] - The company focuses on enhancing the standard of care for bevacizumab in treating retina diseases [3] Company Overview - Outlook Therapeutics is a biopharmaceutical company developing ONS-5010/LYTENAVA™ (bevacizumab-vikg) to improve the treatment of retina diseases [3] - LYTENAVA™ is the first ophthalmic formulation of bevacizumab to receive marketing authorization from the European Commission and MHRA for wet AMD [3] - The commercial launch of LYTENAVA™ has commenced in Germany and the UK for wet AMD treatment [3] Investigational Status - In the United States, ONS-5010/LYTENAVA™ is currently investigational [4] - If approved, it would be the first ophthalmic formulation of bevacizumab for retinal indications, including wet AMD [4]

Core Insights - The FDA has accepted the resubmission of the Biologics License Application (BLA) for ONS-5010 (bevacizumab-vikg), with a Prescription Drug User Fee Act (PDUFA) goal date set for December 31, 2025, marking a significant milestone for Outlook Therapeutics in bringing the first FDA-approved ophthalmic formulation of bevacizumab for wet age-related macular degeneration (wet AMD) to the U.S. market [1][2][7] Company Overview - Outlook Therapeutics is a biopharmaceutical company focused on developing and commercializing ONS-5010/LYTENAVA™ (bevacizumab-vikg) to enhance the standard of care for retinal diseases, particularly wet AMD [6] - The company has commenced the commercial launch of LYTENAVA™ in Germany and the UK, where it has received Marketing Authorization from the European Commission and the Medicines and Healthcare products Regulatory Agency (MHRA) [6] Product Details - ONS-5010/LYTENAVA™ is an investigational ophthalmic formulation of bevacizumab produced in the U.S. for treating wet AMD, which is currently under review in the U.S. [3][4][7] - Bevacizumab-vikg is a recombinant humanized monoclonal antibody that binds to all isoforms of human vascular endothelial growth factor (VEGF), neutralizing its activity and reducing endothelial cell proliferation and vascular leakage in the retina [5]

Core Viewpoint - Outlook Therapeutics has re-submitted its Biologics License Application (BLA) for ONS-5010 to the FDA, aiming for approval of its ophthalmic formulation of bevacizumab for treating wet age-related macular degeneration (wet AMD) [1][2] Company Overview - Outlook Therapeutics is a biopharmaceutical company focused on developing and commercializing ONS-5010/LYTENAVA™ (bevacizumab-vikg) to optimize the standard of care for retinal diseases [6] - The company has commenced the commercial launch of LYTENAVA™ in Germany and the UK for wet AMD treatment [6] Product Details - ONS-5010/LYTENAVA™ is an investigational ophthalmic formulation of bevacizumab produced in the U.S. for wet AMD [3][7] - If approved in the U.S., it would be the first approved ophthalmic formulation of bevacizumab for retinal indications, including wet AMD [7] - LYTENAVA™ has received centralized Marketing Authorization from the European Commission and the MHRA in the UK for wet AMD treatment [3][4] Regulatory Progress - The resubmission of the BLA is seen as a significant step in addressing issues raised in the Complete Response Letter (CRL) received in August 2025 [2] - The company is accelerating its commercial efforts in Europe while preparing for potential near-term U.S. approval [2]

Core Viewpoint - Outlook Therapeutics, Inc. has completed a Type A Meeting with the FDA regarding the complete response letter for its biologics license application for ONS-5010, an investigational treatment for wet AMD, and plans to resubmit the application by the end of 2025 [1][2] Company Overview - Outlook Therapeutics is focused on developing and commercializing ONS-5010/LYTENAVA™ (bevacizumab-vikg) to optimize the standard of care for retinal diseases [6] - The company has commenced the commercial launch of LYTENAVA™ in Germany and the UK for the treatment of wet AMD [6] Product Information - ONS-5010/LYTENAVA™ is an ophthalmic formulation of bevacizumab aimed at treating wet AMD and has received centralized Marketing Authorization in the EU and the UK [3][4] - If approved in the U.S., ONS-5010/LYTENAVA™ would be the first ophthalmic formulation of bevacizumab for retinal indications, including wet AMD [7] Regulatory Discussion - The FDA meeting was described as productive, and the company is awaiting written minutes to finalize its plans for resubmission of the BLA [2] - The company remains committed to providing a safe and effective treatment for patients, physicians, and payors in the U.S. [2]

Core Insights - Outlook Therapeutics, Inc. is focused on optimizing the standard of care for bevacizumab in treating retinal diseases [1][2] - The company will present at the EURETINA Congress on September 3, 2025, discussing advancements in retinal disease treatment [1] - ONS-5010/LYTENAVA™ is the first ophthalmic formulation of bevacizumab to receive marketing authorization in Europe for wet AMD [2] Company Overview - Outlook Therapeutics is a biopharmaceutical company dedicated to the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg) [2] - The commercial launch of LYTENAVA™ has commenced in Germany and the UK for the treatment of wet AMD [2] - In the United States, ONS-5010/LYTENAVA™ is currently investigational and would be the first approved ophthalmic formulation of bevacizumab for retinal indications if approved [3]

Core Viewpoint - Outlook Therapeutics, Inc. received a complete response letter (CRL) from the FDA regarding its biologics license application (BLA) for ONS-5010, indicating that the application cannot be approved in its current form for the treatment of wet age-related macular degeneration (wet AMD) [1][2][3] Group 1: FDA Response and Efficacy - The CRL cited a single deficiency related to a lack of substantial evidence of effectiveness, specifically noting that ONS-5010 did not meet the primary efficacy endpoint in the NORSE EIGHT trial [2] - The FDA recommended that confirmatory evidence of efficacy be submitted to support the application for ONS-5010, while also acknowledging that the NORSE TWO trial met its primary endpoint for effectiveness [2] Group 2: Company Response and Future Plans - The company expressed disappointment with the FDA's decision but plans to meet with the FDA for further clarification on approval requirements for ONS-5010 [3] - Outlook Therapeutics remains committed to providing a safe and effective alternative to compounded Avastin and intends to continue expanding into additional markets in Europe [3] - LYTENAVA™ (bevacizumab gamma) has already received Marketing Authorization in the EU and the UK for the treatment of wet AMD and became commercially available in Germany and the UK in June 2025 [3][10] Group 3: Product Information - ONS-5010/LYTENAVA™ is an ophthalmic formulation of bevacizumab specifically designed for the treatment of wet AMD [7][10] - If approved in the U.S., ONS-5010/LYTENAVA™ would be the first approved ophthalmic formulation of bevacizumab for retinal indications, including wet AMD [11]

Company Overview - Outlook Therapeutics, Inc. is a biopharmaceutical company focused on enhancing the standard of care for bevacizumab in the treatment of retinal diseases [3] - The company is developing ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma), which is the first ophthalmic formulation of bevacizumab to receive marketing authorization from the European Commission and MHRA for treating wet AMD [3] - The commercial launch of LYTENAVA™ has commenced in Germany and the UK for the treatment of wet AMD [3] Regulatory Status - In the United States, ONS-5010/LYTENAVA™ is currently investigational, with a Biologics License Application (BLA) resubmitted to the FDA [4] - If approved, ONS-5010/LYTENAVA™ would be the first approved ophthalmic formulation of bevacizumab for retinal indications, including wet AMD [4] Industry Event - Outlook Therapeutics will present at the 8th Annual OIS Retina Innovation Summit on July 29, 2025, in Long Beach, CA [1] - The presentation will be part of the Innovation Showcase, led by CEO Bob Jahr [1] - The Ophthalmology Innovation Summit aims to showcase novel therapies for unmet needs in ophthalmic diseases and vision disorders, facilitating connections among entrepreneurs, clinical leaders, and investment professionals [2]